Open AccessThe efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
Author(s) -
Tengfei Zhang,
Jing Xie,
Seiji Arai,
Liping Wang,
Xuezhong Shi,
Ni Shi,
Fen Ma,
Sen Chen,
Lan Huang,
Li Yang,
Wang Ma,
Bin Zhang,
Weidong Han,
JianChuan Xia,
Chen Hu,
Yi Zhang
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.12230
Subject(s) - medicine , refractory (planetary science) , pd l1 , antibody , meta analysis , oncology , immunology , immunotherapy , cancer research , cancer , biology , astrobiology
To systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-L1 antibodies for treatment of patients with advanced or refractory cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom